Premium
Outcome of Pyriform Sinus Cancer
Author(s) -
Marks Steven C.,
Lolachi Christopher M.,
Shamsa Falah,
Robinson Kevin,
Aref Amr,
Jacobs John R.
Publication year - 1996
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1097/00005537-199601000-00006
Subject(s) - pyriform sinus , medicine , surgery , radiation therapy , cancer , survival rate , retrospective cohort study , sinus (botany) , overall survival , chemotherapy , fistula , botany , biology , genus
Pyriform sinus cancer remains one of the most lethal of human diseases. Regardless of approach attempted significant enhancement of survival has not been realized. In this study a retrospective single institutional review of all patients diagnosed with pyriform sinus cancer during the 1980s was conducted. The results in 93 patients show an overall determinant 5‐year survival of 14.3%. Of patients undergoing surgery, median determinant survival was 37 months and 5‐year survival was 34.6%. In resectable patients treated with radiation with or without chemotherapy, median determinant survival was 13 months with 5‐year survival of 7.1% ( P <.01). Surgical salvage was attempted in 8 patients without success. In conclusion, due to the apparent survival advantage for surgical patients, the low rate of surgical salvage, and the relatively low rate of organ preservation in prospective trials, pyriform sinus cancer is a poor site for organ preservation. Surgery followed by radiation therapy should remain the standard of care for pyriform sinus cancer.